Stock analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for Sanofi in a report released on ...
Banks including Goldman Sachs Group Inc. and Citigroup Inc. have wrapped up a €7.45 billion ($8.1 billion) sale of leveraged ...
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...
In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
French pharma major Sanofi (Euronext: SAN) today revealed it has entered into a definitive agreement with privately-held US biotech Dren Bio, to acquire the latter’s DR-0201, a targeted bispecific ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback